Lv63
3030 积分 2022-08-17 加入
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
1个月前
已完结
Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma
1个月前
已完结
CS2164, a novel multi‐target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti‐tumor potency
2个月前
已完结
Business beyond the box : applying your mind for breakthrough results
4个月前
已完结
Phase II study of chidamide (CS055), a new subtype-selective oral histone deacetylase inhibitor, in patients with relapsed or refractory peripheral T-cell lymphoma
5个月前
已关闭
皖公网安备34019202002308
